Cocrystal Pharma, Inc. (NASDAQ:COCP – Get Free Report) was the target of a significant growth in short interest in November. As of November 15th, there was short interest totalling 8,000 shares, a growth of 300.0% from the October 31st total of 2,000 shares. Based on an average daily trading volume, of 18,100 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.1% of the shares of the stock are short sold.
Cocrystal Pharma Stock Performance
Shares of COCP traded down $0.08 during midday trading on Friday, hitting $2.02. The company had a trading volume of 4,055 shares, compared to its average volume of 21,017. The company’s 50-day simple moving average is $1.89 and its 200-day simple moving average is $2.03. Cocrystal Pharma has a 1 year low of $1.33 and a 1 year high of $3.10. The firm has a market capitalization of $20.54 million, a P/E ratio of -1.14 and a beta of 1.45.
Analyst Upgrades and Downgrades
Separately, HC Wainwright dropped their price target on Cocrystal Pharma from $10.00 to $7.00 and set a “buy” rating for the company in a research report on Thursday, August 22nd.
Cocrystal Pharma Company Profile
Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.
Read More
- Five stocks we like better than Cocrystal Pharma
- NYSE Stocks Give Investors a Variety of Quality Options
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- The 3 Best Blue-Chip Stocks to Buy Now
- 3 Penny Stocks Ready to Break Out in 2025
- Insider Trading – What You Need to Know
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.